Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

Ceri E Oldreive, PhD, Anna Skowronska, PhD, Angelo Agathanggelou, PhD, Helen M Parry, Sergey Krysov, Graham K Packham, PhD, Rudzki Zbgniew, Guy Pratt, A. Malcolm R Taylor, PhD, Paul Moss, MDPhD, Tatjana Stankovic, MD PhD

Blood (2014) 124 (21): 3284.

https://doi.org/10.1182/blood.V124.21.3284.3284

Published: 2014

Journal Articles

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

Anna Skowronska, Gulshanara Ahmed, Ceri E Oldreive, PhD, David Oscier, MD, Anton Parker, Martin J.S. Dyer, MA, DPhil, Estella Matutes, MD, PhD, A. Malcolm R Taylor, PhD, Paul AH Moss, MD PhD, Tatjana Stankovic, MD PhD

Blood (2011) 118 (21): 467.

https://doi.org/10.1182/blood.V118.21.467.467

Published: 2011

Journal Articles

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

Angelo Agathanggelou, PhD, Anastasia Zlatanou, PhD, Ahmed Gulshanara, MSc, Grant Stewart, PhD, Pamela R Kearns, BSc, MBBCh, MRCP, PhD, Guy Pratt, MD, Paul AH Moss, MD PhD, A. Malcolm R Taylor, PhD, Frederic Colland, PhD, Tatjana Stankovic, MD, PhD

Blood (2011) 118 (21): 3865.

https://doi.org/10.1182/blood.V118.21.3865.3865

Published: 2011

Journal Articles

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

Ceri E Oldreive, PhD, Victoria J Weston, PhD, Paul AH Moss, MD, PhD, Guy Pratt, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 2439.

https://doi.org/10.1182/blood.V116.21.2439.2439

Published: 2010

Journal Articles

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

David Da Costa, Victoria J Weston, PhD, Stefan Knapp, PhD, A. Malcolm R Taylor, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 3238.

https://doi.org/10.1182/blood.V116.21.3238.3238

Published: 2010

Journal Articles

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

Victoria J Weston, PhD, Angelo Agathanggelou, PhD, Paul AH Moss, MD, PhD, Pamela R. Kearns, BSc, MBBCh, MRCP, PhD, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD, PhD

Blood (2010) 116 (21): 49.

https://doi.org/10.1182/blood.V116.21.49.49

Published: 2010

Journal Articles

Large Scale Screening for DNA Damage-Induced Transcription Factors as Potential Targets for Treatment of CLL with p53 Apoptotic Defect.

Victoria Weston, PhD, Paul Moss, MBBS, PhD, FRCP, A. Malcolm R Taylor, PhD, Tatjana Stankovic, MD., PhD

Blood (2009) 114 (22): 3439.

https://doi.org/10.1182/blood.V114.22.3439.3439

Published: 2009

NARROW

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

Large Scale Screening for DNA Damage-Induced Transcription Factors as Potential Targets for Treatment of CLL with p53 Apoptotic Defect.

Email alerts

ASH Publications

American Society of Hematology

Primary CLL Xenograft: A Model System to Study the Role of T-Cells in CLL Biology and Therapeutic Response

Biallelic ATM Inactivation Significantly Reduces Survival in Chronic Lymphocytic Leukemia Patients Treated with Alkylating Agent/Purine Analogue Therapy: Results From the UKCLL4 Trial

New Therapeutic Strategy for Sensitisation of CLL Cells with Inactivation of the DNA Damage Response by Targeting the Deubiquitylating Enzyme USP7-Dependent Pathways,

CLL Xenograft Models to Address the Impact of Single Gene Loss (ATM) on Proliferation and Cytotoxic Response

The PIM Kinase Inhibitor K00135 Sensitizes Primary Acute Lymphoblastic Leukaemia (ALL) Cells to DNA-Damaging Agents

ATM Mutant Lymphoid Tumour Cells Exhibit Impaired Activation of the Redox-Sensitive Nrf2-ARE Detoxification Pathway and Are Differentially Sensitive to Nrf2-Activating Compounds

Large Scale Screening for DNA Damage-Induced Transcription Factors as Potential Targets for Treatment of CLL with p53 Apoptotic Defect.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only